Page last updated: 2024-11-12
norsecurinine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
norsecurinine: isolated from Phyllanthus niruri; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Related Flora
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Phyllanthus | genus | A plant genus of the family EUPHORBIACEAE. Bahupatra (MEDICINE, AYURVEDIC) is prepared from this.[MeSH] | Phyllanthaceae | [no description available] |
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 11106439 |
| SCHEMBL ID | 20558492 |
| MeSH ID | M0143577 |
Synonyms (17)
| Synonym |
|---|
| norsecurinine |
| (-)-norsecurinine |
| 2650-35-3 |
| nor-securinine |
| a-norsecurinan-11-one |
| opf6a516xh , |
| unii-opf6a516xh |
| ent-norsecurinine |
| SCHEMBL20558492 |
| 6,10b-methano-10bh-furo(2,3-c)pyrrolo(1,2-a)azepin-2(6h)-one, 8,9,10,10a-tetrahydro-, (6s-(6.alpha.,10a.beta.,10b.alpha.))- |
| (6s,10ar,10bs)-8,9,10,10a-tetrahydro-6,10b-methano-10bh-furo(2,3-c)pyrrolo(1,2-a)azepin-2(6h)-one |
| 6,10b-methano-10bh-furo(2,3-c)pyrrolo(1,2-a)azepin-2(6h)-one, 8,9,10,10a-tetrahydro-, (6s,10ar,10bs)- |
| DTXSID40949368 |
| (1s,8s,13r)-2-oxa-9-azatetracyclo[6.5.1.01,5.09,13]tetradeca-4,6-dien-3-one |
| 6,10b-methano-10bh-furo[2,3-c]pyrrolo[1,2-a]azepin-2(6h)-one, 8,9,10,10a-tetrahydro-, (6s,10ar,10bs)- |
| 6,10b-methano-10bh-furo(2,3-c)pyrrolo(1,2-a)azepin-2(6h)-one, 8,9,10,10a-tetrahydro-, (6s-(6alpha,10abeta,10balpha))- |
| AKOS040740313 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||